Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg(University of Pittsburgh Medical Center), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Antonio Jimeno(University of Colorado Cancer Center), Moon J. Fenton(University of Tennessee Health Science Center), Nathaniel Bouganim(McGill University Health Centre), Jérôme Fayette(Université Claude Bernard Lyon 1), Éva Remenár(National Institute of Oncology), Jean Fan(Johns Hopkins University), Kobby Asubonteng(AstraZeneca (United States)), Ulrich Keilholz(German Cancer Research Center), Alain P. Algazi(University of California, San Francisco), Zsuzsanna Pápai(National Institute of Oncology), Stéphanie Henry(CHU Dinant Godinne UCL Namur), Irene Braña(Vall d'Hebron Institute of Oncology), Neal Ready(Duke University), J. Armstrong(AstraZeneca (United States)), Stuart J. Wong(Medical College of Wisconsin), Anthony Jarkowski(AstraZeneca (United States)), Paul Clement(KU Leuven), Jill Gilbert(Cancer Clinic), Caroline Even(Institut Gustave Roussy), Raymond Jang(University of Toronto), Giovanni Melillo(AstraZeneca (Brazil)), James Good(Queen Elizabeth Hospital Birmingham), Lillian L. Siu(University Health Network)
Cited by 267
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k